CenterBook Partners’s NewAmsterdam Pharma NAMS Stock Holding History

CenterBook Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-22,254	Closed	-$712K	–	811
2026 Q1	$712K	Buy	22,254 +10,194	+85%	+$332K	0.04%	415
2025 Q4	$423K	Sell	12,060 -58,553	-83%	-$2.13M	0.02%	500
2025 Q3	$2.01M	Buy	70,613 +2,423	+4%	+$58.1K	0.1%	258
2025 Q2	$1.23M	Sell	68,190 -154,074	-69%	-$2.81M	0.07%	307
2025 Q1	$4.55M	Buy	222,264 +13,675	+7%	+$304K	0.29%	95
2024 Q4	$5.36M	Buy	208,589 +122,894	+143%	+$2.61M	0.32%	89
2024 Q3	$1.42M	Buy	+85,695	New	+$1.48M	0.09%	252

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

CenterBook Partners's NAMS Position: Q2 2026 in Review

CenterBook Partners sold out of NewAmsterdam Pharma (NAMS) in Q2 2026, closing a stake of 22,254 shares — an estimated $712K sold.

CenterBook Partners first reported a position in NAMS in Q3 2024 and held it in 7 quarters. The position peaked at $5.36M in Q4 2024. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

CenterBook Partners reported no remaining NewAmsterdam Pharma position as of Q2 2026 after selling out during the quarter.
CenterBook Partners sold 22,254 NewAmsterdam Pharma shares in Q2 2026, an estimated $712K.
CenterBook Partners first reported a position in NewAmsterdam Pharma in Q3 2024 and held it in 7 quarters.
CenterBook Partners's NewAmsterdam Pharma position peaked at $5.36M in Q4 2024.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.